OrbiMed’s Damora Therapeutics DMRA Stock Holding History

OrbiMed’s Portfolio DMRA Stock Details DMRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-36,992	Closed	-$665K	–	123
2023 Q3	$665K	Sell	36,992 -116,377	-76%	-$4.57M	0.01%	123
2023 Q2	$9.66M	Sell	153,369 -10,268	-6%	-$559K	0.18%	88
2023 Q1	$8.14M	Hold	163,637	–	–	0.16%	90
2022 Q4	$4.7M	Hold	163,637	–	–	0.09%	95
2022 Q3	$7.73M	Hold	163,637	–	–	0.14%	93
2022 Q2	$7.08M	Hold	163,637	–	–	0.13%	102
2022 Q1	$9M	Hold	163,637	–	–	0.15%	103
2021 Q4	$12.4M	Hold	163,637	–	–	0.16%	110
2021 Q3	$14.7M	Hold	163,637	–	–	0.16%	111
2021 Q2	$20.7M	Hold	163,637	–	–	0.21%	98
2021 Q1	$24.9M	Hold	163,637	–	–	0.23%	88
2020 Q4	$51.2M	Buy	+163,637	New	+$60.9M	0.45%	62

Other funds holding DMRA

NHAS

Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return

TSS

Two Sigma Securities New York $1.16B AUM 36.23% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

OrbiMed's DMRA Position: Q4 2023 in Review

OrbiMed sold out of Damora Therapeutics (DMRA) in Q4 2023, closing a stake of 36,992 shares — an estimated $665K sold.

OrbiMed first reported a position in DMRA in Q4 2020 and held it in 12 quarters. The position peaked at $51.2M in Q4 2020. 21 funds tracked by Wall St. Rank hold DMRA as of Q4 2023.

OrbiMed reported no remaining Damora Therapeutics position as of Q4 2023 after selling out during the quarter.
OrbiMed sold 36,992 Damora Therapeutics shares in Q4 2023, an estimated $665K.
OrbiMed first reported a position in Damora Therapeutics in Q4 2020 and held it in 12 quarters.
OrbiMed's Damora Therapeutics position peaked at $51.2M in Q4 2020.
21 funds tracked by Wall St. Rank held Damora Therapeutics as of Q4 2023.

Based on OrbiMed's 13F filing for Q4 2023, filed 14 Feb 2024.